13 December 2007

Vasopressin caution in septic shock

Vasopressin should be used with great caution for the treatment of hypotension in septic shock, according to results from an international research team published today in the online open access journal Critical Care. Their experiments - conducted in pigs - show it can significantly reduce blood flow to vital organs.

The peptide hormone vasopressin is being developed as a new therapy for the hemodynamic support of septic shock and vasodilatory shock due to systemic inflammatory response syndrome.

Previously, the compound has been shown to increase blood pressure in septic shock that fails to respond to catecholamines. However, the safety of vasopressin treatment in humans with septic shock is yet to be proven. Now, researchers in Iceland, Switzerland, and the US, have tested the effects of vasopressin on pancreatic, renal, and hepatic perfusion in pigs and discovered that the compound causes severe disturbances in blood flow in these organs.

Dr Vladimir Krejci of the Department of Anesthesiology, Washington University School of Medicine, in St. Louis, Missouri, and colleagues investigated the effects of vasopressin on pigs divided into in four groups. Group S (sepsis) and group SV (sepsis/vasopressin) were exposed to fecal peritonitis, while Group C and Group V were non-septic controls. The team measured regional blood flow in the hepatic and renal arteries, the portal vein, and the celiac trunk by means of ultrasonic transit time flowmetry.

They found that in septic shock, vasopressin markedly decreased blood flow (by 58%) in the portal vein within an hour, and even after three hours the reduction stood at 45%. Flow was unchanged in the hepatic artery and increased in the celiac trunk, but was unchanged in the liver. Microcirculatory blood flow in the pancreas also fell considerably and, to a lesser extent, in the kidney. The investigation also revealed that increased urine output does not necessarily reflect increased renal blood flow and so may not be a useful indicator of the effects of a particular treatment.

# # #

Article:
Vasopressin in septic shock
Vladimir Krejci, Luzius B Hiltebrand, Stephan M Jakob, Jukka Takala and Gisli H Sigurdsson
Critical Care 2007, 11:R129 (13 December 2007)

Journal website:
http://ccforum.com/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Please name the journal in any story you write, and link to the article if you are writing for the web.

For more information about this study, or about the journal, contact Charlotte Webber by email at press@biomedcentral.com or by phone on +44 (0)20 7631 9980

# # #

BioMed Central is an independent online publishing house committed to providing open access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science.

BioMed Central currently publishes over 160 journals across biology and medicine. In addition to open-access original research. BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.